Axsome Therapeutics (AXSM) Total Current Liabilities (2015 - 2026)

Axsome Therapeutics has reported Total Current Liabilities for 12 years, with the latest figure at $439.2 million in Q1 2026.

• Quarterly Total Current Liabilities rose 80.07% year-over-year to $439.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $439.2 million (up 80.07% YoY) and the FY2025 annual result came in at $378.8 million, up 64.64% from the prior year.
• Total Current Liabilities grew to $439.2 million in Q1 2026 per AXSM's latest filing, from $378.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $439.2 million in Q1 2026 and troughed at $24.5 million in Q1 2022.
• A 5-year average of $189.1 million and a median of $144.0 million in 2024 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 318.64% in 2022, down 13.22% in 2022.
• Over 5 years, Total Current Liabilities stood at $96.6 million in 2022, then soared by 43.8% to $138.9 million in 2023, then soared by 65.72% to $230.1 million in 2024, then jumped by 64.64% to $378.8 million in 2025, then climbed by 15.94% to $439.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $439.2 million, $378.8 million, and $360.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.